Alluvi, previously BI 4744, presents a significant development in obesity therapy. This dual agonist targeting both GLP-1 and GIP receptors demonstrates compelling efficacy in clinical assessments, possibly surpassing https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/